menu
    • menu

    Company profile for Immutep

    NEW Drugs in Dev: 7
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immutep is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Immutep's main pipeline of products is based on the LAG-3 immune ...
    Immutep is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Immutep's main pipeline of products is based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The most clinically advanced product is a T cell immunostimulatory factor (APC activator)

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmutepAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 12, 95 Pitt Street Sydney, NSW 2000
    Telephone
    Telephone
    +61 2 9290 9600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immutep.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/857541/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/immutep?lang=en/

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immutep Reports Phase I LAG-3 Progress in Autoimmune Diseases
    Immutep Reports Phase I LAG-3 Progress in Autoimmune Diseases

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258946/0/en/Immutep-Reports-Progress-from-Phase-I-Study-of-LAG-3-Agonist-for-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Immutep's Ph. 3 Failure Surprises Analysts, Sinks Stock
    Immutep's Ph. 3 Failure Surprises Analysts, Sinks Stock

    14 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/immuteps-phase-3-failure-immunotherapy-surprises-analysts-sinks-stock

    FIERCE BIOTECH
    14 Mar 2026
    Share Share
    Immutep Teams Up With Flex Databases For Clinical Trial
    Immutep Teams Up With Flex Databases For Clinical Trial

    10 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-10/immutep-partners-with-flex-databases-to-digitize-clinical-trial-documentation

    PHARMIWEB
    10 Mar 2026
    Share Share
    Immutep Reaches 50% Enrollment In Global Phase III Trial For 1L
    Immutep Reaches 50% Enrollment In Global Phase III Trial For 1L

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233774/0/en/Immutep-Achieves-50-Enrolment-in-Global-TACTI-004-KEYNOTE-F91-Phase-III-Trial-in-1L-NSCLC.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Immutep Q2 FY26 Quarterly Activities Report
    Immutep Q2 FY26 Quarterly Activities Report

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228526/0/en/Immutep-Quarterly-Activities-Report-Q2-FY26.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Immutep Reports Strong Progress in TACTI-004 Phase III Trial
    Immutep Reports Strong Progress in TACTI-004 Phase III Trial

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206183/0/en/Immutep-Announces-Strong-Operational-Progress-in-Global-TACTI-004-KEYNOTE-F91-Phase-III-and-Enrolment-Continues-at-Robust-Pace.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Contact Immutep and get a quotation

    Immutep is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Eftilagimod Alpha bulk offered by Immutep

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search